Organon in the news

Organon stock is a merger-arbitrage hold due to an approved acquisition by Sun Pharma at $14.00 per share, with limited upside and weak business fundamentals.

Organon (OGN) is attracting investor interest due to recent stock performance and upcoming earnings estimates.

Henlius signed a deal worth up to $541 million with Organon for the exclusive ex-China commercialization of its HLX11 and HLX14 biosimilar candidates.

Sun Pharma has completed securing $11.75 billion in financing from a syndicate of 11 banks for its acquisition of Organon, aiming to significantly expand its global pharmaceutical market presence.

Organon shareholders approved the merger with Sun Pharmaceutical Holdings USA, making Organon a wholly owned subsidiary of Sun Pharma USA.

Organon committed over $1.3 million to the UNFPA to support women's sexual and reproductive health programs across nine countries.

Sun Pharma's acquisition of Organon is a transformative move, expanding its international footprint, strengthening its biosimilars and women's health portfolios, and creating a global pharmaceutical powerhouse.

White & Case advised Sun Pharma on its acquisition of Organon for $11.75 billion, expanding Sun Pharma's portfolio in women's health and general medicines.

Sun Pharmaceutical Industries is buying Organon for $11.75 billion to expand its women's health and biosimilars portfolios.

Sun Pharma acquired Organon for $11.75 billion to expand its innovative medicine and biosimilar portfolio, despite Organon's recent financial struggles.

Organon shares are undervalued with no clear growth drivers, and the company needs a new development strategy.

Organon & Co. faces mostly negative analyst ratings and a declining stock price despite recent earnings beats and institutional investor interest.

Organon is using TetraScience's platform to automate quality control data management, reducing analysis time and improving compliance in drug manufacturing.

Laborie is acquiring Organon's JADA System, an FDA-cleared postpartum bleeding device, for up to $465 million to expand its obstetrics portfolio.

Organon addressed improper Nexplanon sales practices involving channel stuffing, implemented leadership changes, and confirmed no material financial restatement was needed.

Organon's CEO resigned after an internal probe found improper sales tactics boosting Nexplanon sales, leading to leadership changes and stock decline.

Organon is divesting its Jada System to Laborie for up to $465 million to reduce debt and focus on other women's health opportunities amid recent business challenges.

FDA approved Poherdy, the first pertuzumab biosimilar in the U.S., for treating HER2-positive breast cancer, with Organon holding exclusive commercialization rights outside China.

Organon Vietnam and UNFPA partnered to improve reproductive health information and services for women and youth in Vietnam, addressing high adolescent fertility and contraceptive gaps.

Henlius and Organon gained FDA approval for Poherdy, the first interchangeable biosimilar to Perjeta.